148 related articles for article (PubMed ID: 27238880)
1. Case of severe ulceration induced by pazopanib.
Goto H; Niwakawa M; Yoshikawa S; Otsuka M; Omodaka T; Yoshimi K; Kiyohara Y
J Dermatol; 2017 Apr; 44(4):474-476. PubMed ID: 27238880
[No Abstract] [Full Text] [Related]
2. [Atrial flutter probably related to pazopanib: A case report].
Puebla Villaescusa A; Díaz Gómez E; Salcedo Mingoarranz ÁL; Ramírez Cruz S; Hidalgo Correas FJ; García Díaz B
Farm Hosp; 2018 Jan; 42(1):33-34. PubMed ID: 29306315
[No Abstract] [Full Text] [Related]
3. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome: A Case Report.
Singh P; DʼAngelo RN; Huang V
Am J Ther; 2019; 26(5):e636-e638. PubMed ID: 30946042
[No Abstract] [Full Text] [Related]
5. Subacute cutaneous lupus erythematosus induced by the new multikinase inhibitor pazopanib.
Casado-Verrier B; Pérez-Santos S; Delgado-Mucientes C; Beato-Merino M
Br J Dermatol; 2014 Dec; 171(6):1559-61. PubMed ID: 24909204
[No Abstract] [Full Text] [Related]
6. Benefits of pazopanib over sunitinib for renal cell carcinoma.
Granovetter M
Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
[No Abstract] [Full Text] [Related]
7. A rare case: Hallucination associated with pazopanib.
Demirci NS; Erdem GU; Dogan M; Ozdemir NY; Zengin N
J Cancer Res Ther; 2015; 11(4):961-2. PubMed ID: 26881556
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report.
Abdallah AO; Vallurupalli S; Kunthur A
J Oncol Pharm Pract; 2016 Jun; 22(3):561-5. PubMed ID: 25956420
[No Abstract] [Full Text] [Related]
9. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
Klempner SJ; Choueiri TK; Yee E; Doyle LA; Schuppan D; Atkins MB
J Clin Oncol; 2012 Sep; 30(27):e264-8. PubMed ID: 22802316
[No Abstract] [Full Text] [Related]
10. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
11. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
Beaumont JL; Salsman JM; Diaz J; Deen KC; McCann L; Powles T; Hackshaw MD; Motzer RJ; Cella D
Cancer; 2016 Apr; 122(7):1108-15. PubMed ID: 27000445
[TBL] [Abstract][Full Text] [Related]
12. Guillain-Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy.
Koshikawa H; Tsukie T; Kurita A; Fujikura M; Suzuki M; Araki K
J Infect Chemother; 2017 Nov; 23(11):798-799. PubMed ID: 28506529
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma.
Harada Y; Kakimoto S; Shimizu T
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32641305
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
[TBL] [Abstract][Full Text] [Related]
15. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L
Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763
[TBL] [Abstract][Full Text] [Related]
16. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
[TBL] [Abstract][Full Text] [Related]
17. External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib.
Okamura Y; Hinata N; Terakawa T; Furukawa J; Harada K; Nakano Y; Nakamura I; Inoue T; Ogawa T; Fujisawa M
Int J Clin Oncol; 2019 Jun; 24(6):698-705. PubMed ID: 30798395
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report.
Bersanelli M; Facchinetti F; Tiseo M; Maiorana M; Buti S
Curr Drug Targets; 2016; 17(15):1755-1760. PubMed ID: 26758665
[TBL] [Abstract][Full Text] [Related]
19. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
[TBL] [Abstract][Full Text] [Related]
20. Panniculitis in a patient with metastatic renal cell carcinoma on a tyrosine kinase inhibitor.
Nafissi NN; Karlin N; Pittelkow MR; Dicaudo DJ; Mangold AR
Anticancer Drugs; 2021 Apr; 32(4):474-475. PubMed ID: 33290313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]